Overview

A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease

Status:
Active, not recruiting
Trial end date:
2021-10-22
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of a study drug that targets an abnormal protein in the brain found in people with Alzheimer's Disease (AD).
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company